As mentioned above, a recent study showed that LPS-RS, a TLR4 antagonist, reduces the expression of TRIF in the LV hypertrophy model caused by hyperoxia exposure, but not MyD88 (99). The gene discussed is MYD88; the disease is cardiac hypertrophy.